Chromatin remodeling protein MORC2 promotes breast cancer invasion and metastasis through a PRD domain-mediated interaction with CTNND1

Xiao-Hong Liao¹,²,³,*, Ye Zhang¹,*, Wen-Jie Dong¹,²,³, Zhi-Min Shao¹,²,³,⁴,⁵ and Da-Qiang Li¹,²,³,⁴,⁵

¹Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China
²Department of Oncology, Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China
³Cancer Institute, Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China
⁴Department of Breast Surgery, Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China
⁵Key Laboratory of Breast Cancer in Shanghai, Shanghai Medical College, Fudan University, Shanghai 200032, China

*These authors contributed equally to this work

Correspondence to: Zhi-Min Shao, email: zhimingshao@yahoo.com
Da-Qiang Li, email: daqiangli1974@fudan.edu.cn

Keywords: breast cancer, invasion and metastasis, protein-protein interaction, MORC2, proline-rich domain

Received: April 13, 2017 Accepted: June 05, 2017 Published: June 16, 2017

ABSTRACT

MORC family CW-type zinc finger protein 2 (MORC2) is a newly identified chromatin remodeling protein with emerging roles in the regulation of DNA damage response and gene transcription, but its mechanistic role in breast cancer development and progression remains unexplored. Here, we show that MORC2 promoted breast cancer invasion and metastasis and these effects depended on a proline-rich domain (PRD) within its carboxy-terminal region spanning residues 601–734. Induced expression of wild-type MORC2 did not significantly affect cell proliferation and cell-cycle progression, but promoted breast cancer cell migration and invasion in vitro and metastatic lung colonization in vivo. The PRD domain was dispensable for the protein stability and subcellular localization of MORC2, but depletion of the PRD domain substantially suppressed MORC2-mediated migration, invasion, and metastasis. Proteomic and biochemical analyses further demonstrated that wild-type MORC2, but not PRD deletion mutant, interacted with catenin delta 1 (CTNND1), a cadherin-associated protein that participates in tumor invasion and metastasis. Moreover, knockdown of endogenous CTNND1 by short hairpin RNAs suppressed the migratory and invasive potential of MORC2-expressing cells. Taken together, these results suggest that MORC2 promotes breast cancer invasion and metastasis through its PRD domain-mediated interaction with CTNND1.

INTRODUCTION

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality in women worldwide [1]. Clinical evidence shows that over 90% of breast cancer-related death is attributable to distant metastasis to target organs including the lungs [2], liver [3], bones [4], or brain [5]. Despite the significant clinical challenge, the molecular mechanism underlying breast cancer invasion and metastasis has not yet been fully delineated.

MORC family CW-type zinc finger protein 2 (MORC2) is a member of the microorchidia (MORC) nuclear protein superfamily [6]. Although MORC2 is ubiquitously expressed in human cells and tissues [7–9], its biological functions in mammalian cells remain largely
unknown. Recently, we and others defined MORC2 as a global chromatin remodeler with emerging roles in the regulation of DNA damage response [7] and gene transcription [8, 10, 11]. In addition to its nuclear functions, cytosolic MORC2 is implicated in the regulation of lipogenesis and adipocyte differentiation [12]. In human cancer, MORC2 has been shown to promote gastric tumorigenesis [10, 11, 13]. Interestingly, two recent gene expression profiling studies revealed that the expression levels of MORC2 are up-regulated in breast cancer tissues as compared with adjacent normal breast tissues [14] and are associated with recurrence risk of patients with highly aggressive triple-negative breast cancer [15]. However, the mechanistic role for MORC2 in breast cancer development and progression remains unexplored.

The proline-rich domain (PRD) was first identified in the p53 tumor suppressor protein as a region enriched in prolines and containing several repeats of the amino acid motif PXXP (where P indicates proline and X indicates any amino acid) [16]. Subsequent studies further demonstrated that the PRD domain is widely distributed in eukaryotic proteomes and is usually involved in the assembly of multi-protein complexes [17–19]. Moreover, emerging evidence shows that the PRD domain is intimately implicated in the spatial and temporal control of diverse signal transduction events through interaction with specific binding modules, such as the Src homology 3 (SH3), WW, and Enabled/VASP homology-1 (EVH1) domains [20]. Interestingly, analysis of the MORC2 protein sequence revealed the presence of a putative PRD domain within its carboxy-terminal region spanning residues 601–734, but the biological functions of the PRD domain in MORC2 remain largely unknown.

Catenin delta 1 (CTNND1), also known as p120-catenin, was originally identified as a substrate of the oncogenic tyrosine kinase Src [21] and subsequently defined as a component of the adherens junction complex that includes E-cadherin and α-, β-, γ-catenins [22, 23]. Of interest, CTNND1 is a multifaceted intracellular signaling protein, which may function as either a tumor suppressor or a metastasis promoter depending on its subcellular localization and E-cadherin expression status [24, 25]. In this context, a core function of CTNN1D in mammalian cells is to stabilize E-cadherin at cell membrane by preventing its endocytosis and degradation in the lysosome [26–28], thus facilitating E-cadherin-mediated suppression of tumor invasion and metastasis [27, 29–31]. In turn, E-cadherin is both necessary and sufficient for localization of CTNN1D at cell membrane [32, 33]. Consequently, loss of E-cadherin function or expression during tumor progression as a consequence of the epithelial to mesenchymal transition results in the translocation of CTNN1D from cell membrane to the cytoplasm and/or the nucleus [33–37]. In the cytoplasm, CTNND1 promotes cell migration and, consequently, tumor invasion and metastasis through activation of Rho-family GTPases Rac1 and Cdc42 and inhibition of RhoA activity [29, 38–43]. Consistently, the increased cytoplasmic localization of CTNND1 is closely associated with the increased invasive phenotype of E-cadherin-deficient breast cancer cells [29, 33, 35, 44]. In addition, CTNND1 protein contains two putative nuclear localization signals and a nuclear export signal, thus outlining a potential role for CTNND1 in nuclear signaling [36, 45, 46]. Indeed, elevated levels of CTNND1 in the nucleus have been observed in E-cadherin-deficient cancer cells [36, 37], indicating a potential role for nuclear CTNND1 in enhancing the metastatic phenotype associated with E-cadherin downregulation [37]. In addition, CTNND1 has been documented to interact with the transcriptional factor Kaiso [46, 47] and regulate the expression of Kaiso target genes involved in canonical and noncanonical Wnt signaling [48–50]. Together, although CTNND1 is recognized as a key regulator in cancer progression and metastasis, the mechanistic aspects of its prometastatic signaling in breast cancer are not fully characterized.

In this study, we addressed the functional and mechanistic roles for MORC2 in breast cancer development and progression. Findings presented here show that MORC2 promotes breast cancer invasion and metastasis, and the PRD domain is essential for the metastasis-promoting properties of MORC2 through interacting with CTNND1.

RESULTS

The PRD domain is dispensable for the stability and subcellular localization of MORC2

Analysis of the MORC2 amino acid sequence revealed the presence of a putative PRD domain within the C-terminal region spanning residues 601–734 (Figure 1A). This region is rich in the amino acid proline (32/134 residues) and contains 9 copies of canonical PXXP motifs (P designating proline and X designating any amino acid) (Figure 1A). As the functional importance of the PRD domain has been documented in multiple cancer relevant proteins such as p53 (Supplementary Figure 1) [16, 19, 51–56], we set out to address the possible functions of the PRD domain in MORC2.

To do this, we first examined the protein expression levels of endogenous MORC2 in normal mammary epithelial cell lines MCF10A and HBL100, and breast cancer cell lines MCF-7, T47D, SK-BR-3, BT474, MDA-MB-231, MDA-MB-468, Hs578T, and HCC1937. As shown in Figure 1B, MCF-7 and BT474 cells showed high levels of endogenous MORC2, whereas MCF10A, MDA-MB-231, and Hs578T cells expressed low levels of endogenous MORC2. Consistent with the literature [57], estrogen receptor α (ERα) was detected in MCF-7, T47D, and BT474 cells, while human epidermal growth factor receptor 2 (HER2) was highly expressed in SK-
BR-3 and BT474 cells (Figure 1B), indicating that the cell lines used in this study were well authenticated. Second, we generated a MORC2 cDNA deletion mutant (ΔPRD), which lacks this entire PRD domain (deleted for amino acids 601–734). Third, we chose MCF10A, MDA-MB-231, and Hs578T cell lines, which express low levels of endogenous MORC2 (Figure 1B), to generate stable cell lines expressing empty vector pCDH, wild-type MORC2 (Flag-MORC2 WT), and PRD domain deletion mutant MORC2 (Flag-MORC2 ΔPRD) by lentiviral infection. The expression levels of Flag-MORC2 in the resultant cell lines were verified by immunoblotting (Figure 1C).

Given that the PRD domain has been shown to be involved in the regulation of the subcellular localization and stability of some PRD domain-containing proteins [58, 59], we next examined whether the PRD domain of MORC2 could affect its protein stability and subcellular localization. For this purpose, MCF10A, MDA-MB-231 and Hs578T cells stably expressing Flag-MORC2 WT and Flag-MORC2 ΔPRD were treated with 100 μg/ml cycloheximide (CHX), a protein synthesis inhibitor, for the indicated time points and then subjected to immunoblotting analysis with an anti-Flag antibody. Results showed that there were no significant differences in the expression levels of Flag-MORC2 WT and Flag-MORC2 ΔPRD following CHX treatment at various time points (Figure 1D). To determine whether the PRD domain could affect the subcellular localization of MORC2, MDA-MB-231, Hs578T, and MCF10A cells were transiently infected with the lentiviral expression vectors encoding pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD for 48 h, and then indirect immunofluorescence staining was performed using an anti-Flag antibody. 4′,6-diamidino-2-phenylindole (DAPI) was used to detect the nuclei in all cells. The infection efficiency of lentiviral vectors was about 20%, and about 85% transiently expressed Flag-MORC2 and Flag-MORC2 ΔPRD were localized in the nuclei (Figure 1E and Supplementary Figure 2). Taken together, these results suggest that the PRD domain is dispensable for the stability and subcellular localization of MORC2.

Both wild-type MORC2 and PRD deletion mutant MORC2 are not required for cell proliferation and cell-cycle progression of breast cancer cells

To characterize the function of MORC2 and its PRD domain in breast cancer cells, cell proliferation and cell-cycle progression of MCF10A, MDA-MB-231, and Hs578T cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD were evaluated using Cell Counting Kit-8 (CCK-8), colony formation assay, and flow cytometry, respectively. The CCK-8 assays revealed that induced expression of either wild-type MORC2 or PRD deletion mutant did not significantly affect cell viability as compared with empty vector pCDH-infected cells (Figure 2A). Consistently, colony formation assays also demonstrated that there were no significant differences in both the size and the numbers of the colonies among cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD (Figure 2B). In addition, flow cytometry analysis showed that cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD did not show significant differences in cell-cycle distribution (Figure 2C). Collectively, these results suggest that induced expression of both wild-type MORC2 and PRD deletion mutant MORC2 did not significantly affect cell proliferation, colony formation, and cell-cycle progression.

Induced expression of wild-type MORC2, not PRD deletion mutant MORC2, promotes breast cancer cell migration, invasion, and metastasis

As one of the hallmarks of breast cancer is its ability to invade and metastasize [2–5], we next sought to determine the impact of MORC2 protein and its PRD domain on the invasive and metastatic capacity of breast cancer cells. To investigate the involvement of MORC2 and its PRD domain in breast cancer cell migration and invasion in vitro, wound healing (Figure 3A, 3B), transwell migration (Figure 3C, 3D) and invasion assays (Figure 3E, 3F) were performed. Results showed that MDA-MB-231 and Hs578T cells expressing wild-type MORC2 exhibited significantly increased migration (Figure 3A–3D) and invasion (Figure 3E, 3F) capabilities as compared with pCDH expressing cells. Interestingly, depletion of the PRD domain significantly suppressed breast cancer cell migration and invasion (Figure 3A–3F). These results collectively indicate that MORC2 promotes breast cancer migration and invasion in vitro through, at least in part, its PRD domain.

Cell migration and invasion are essential for metastatic dissemination of breast cancer. To test whether MORC2 and its PRD domain affect the ability of breast cancer cells to colonize the lung, MDA-MB-231 cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD were injected into the tail vein of nude mice and the lung metastasis nodules were examined after 6 weeks of injection. Consistent with in vitro experimental findings, induced expression of wild-type MORC2 increased the number of the metastatic lung lesions compared to the empty vector pCDH control (Figure 3G, 3H). In contrast, expression of PRD domain deletion mutant MORC2 reduced the lung metastatic burden (Figure 3G, 3H). These results were further confirmed by analysis of hematoxylin-eosin-stained lung sections (Figure 3I). Together, these data suggests that the PRD domain is important for metastasis-promoting activity of MORC2 in vivo.
MORC2 interacts with CTNND1 in a PRD domain-dependent manner

We next investigated the molecular mechanism by which MORC2 promotes breast cancer invasion and metastasis. As the PRD domain is a putative protein-binding module [20], we next identified the potential binding partners of MORC2 by immunoprecipitation (IP) coupled with liquid chromatography tandem mass spectrometry (LC-MS/MS) method (Figure 4A). To do this, HEK293T cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD were subjected to IP analysis with an anti-Flag antibody (Figure 4B), and the immunoprecipitated proteins were isolated by SDS-PAGE and then stained by Coomassie brilliant blue (Figure 4C). LC-MS/MS analysis showed that 536 proteins specifically interacted with wild-type MORC2, whereas 137 proteins interacted with the PRD deletion mutant MORC2 (Figure 4D). Bioinformatic analysis using DAVID (https://david.ncifcrf.gov) revealed that the biological pathway involving those 536 proteins that specially bind to wild-type MORC2 (Supplementary Table 1) is mainly associated with protein localization and cytoskeleton regulation (Figure 4E).

Next, we analyzed these proteins whose functions are involved in protein localization and cytoskeleton...
regulation by unique peptide numbers and percentage of coverage, and found CTNND1 with the top matching unique peptide and the second highest coverage (Figure 5A). To further confirm these results, total cellular lysates from HEK293T and MCF-7 cells were immunoprecipitated with control IgG or with an anti-MORC2 antibody. Results showed that CTNND1 was detected in the purified MORC2 immune-complex but not control IgG ones (Figure 5B and Supplementary Figure 3A). Reverse IP with an anti-CTNND1 antibody further confirmed these observations (Figure 5C and Supplementary Figure 3B). These results suggest that endogenous MORC2 interacts with endogenous CTNND1 in both HEK293T and MCF-7 cells.

To confirm that the interaction between MORC2 and CTNND1 is dependent on the PRD domain of MORC2, we

Figure 2: MORC2 and its PRD domain are not required for cell proliferation and cell-cycle progression. (A) Cell viability was determined at the indicate time points using CCK-8 kit. (B) Cells were seeded in 6-well plates and cultured for 2 weeks. Cells were staining with 0.1% crystal violet dye and the numbers of colonies were counted. (C) Cell-cycle distribution was analyzed using flow cytometry.
conducted IP analysis using lysates from HEK293T cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD, and found that exogenously transfected wild-type MORC2, but not empty vector pCDH or PRD deletion mutant MORC2, could interact with endogenous CTNND1 (Figure 5D). Next, HEK293T cells were transfected with the plasmids encoding pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD together with GFP-CTNND1 expression vector. After 48 h of transfection, whole-cell lysates were immunoprecipitated with an anti-Flag antibody or an anti-GFP antibody. Immunoblotting analysis showed that the exogenously expressed wild-type MORC2, not PRD deletion mutant MORC2, could interact with exogenously expressed CTNND1 (Figure 5E). These results suggest that MORC2 interacts with CTNND1 in a PRD domain-dependent manner.

The functions of CTNND1 largely depend on its subcellular localization [36, 44]. We next examined whether GFP-CTNND1 and Flag-MORC2 could co-localize in HEK293T cells. To do this, HEK293T cells were transiently transfected with GFP-CTNND1 in combination with pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD. The transfection efficiency was about 33% for GFP-CTNND1 (Supplementary Figure 4A) and 15% for Flag-MORC2 WT and Flag-MORC2 ΔPRD (Supplementary Figure 4B). In cells expressing GFP-CTNND1 alone, GFP-CTNND1 was primarily localized to cell membrane (Figure 5F and Supplementary Figure 4C, upper panel). However, coexpression of wild-type MORC2 caused GFP-CTNND1 re-localization from cell membrane to the cytosol or nucleus, where both proteins could co-localize (Figure 5F and Supplementary Figure 4C, middle panel). When Flag-MORC2 ΔPRD was coexpressed with GFP-CTNND1, the co-localization between Flag-MORC2 ΔPRD and GFP-CTNND1 was not consistently observed (Figure 5F and Supplementary

**Figure 3:** Induced expression of wild-type MORC2, but not PRD deletion mutant MORC2, enhances breast cancer cell migration, invasion and metastasis. (A, B) MDA-MB-231 and Hs578T cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD were subjected to wound-healing assays. Representative images (A) and quantitative results (B) are shown. (C–F) MDA-MB-231 and Hs578T cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD were subjected to transwell migration (C–D) and invasion (E–F) assays. Representative images of cell migration and invasion (C, E) and the corresponding quantitative results (D, F) are shown. (G–I) MDA-MB-231 cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD were injected into 5–6 week-old BALB/c female nude mice (5 mice per group) through the tail vein, and lungs were harvested after 6 weeks of injection. Representative images of lung metastasis (G), corresponding quantitative results of lung nodules (H), and representative images of H&E-stained sections of lung tissues (I) are shown.
Figure 4C, bottom panel). The quantitative results of co-localization of GFP-CTNND1 with Flag-MORC2 and Flag-MORC2 ΔPRD are shown in Figure 5G. These results indicate that exogenously transfected wild-type MORC2, not PRD deletion mutant MORC2, could co-localize with exogenously transfected GFP-CTNND1.

The migration- and invasion-promoting ability of MORC2 depends on the expression of CTNND1

Given that CTNND1 is implicated in the metastatic progression of breast cancer [33, 34, 60] and that MORC2 interacts with CTNND1 (Figure 5), we next assessed the role of CTNND1 in MORC2-enhanced migration and invasion of breast cancer cells. To do this, we knocked down the endogenous CTNND1 in wild-type MORC2 expressing MDA-MB-231 and Hs578T cells using two different short hairpin RNAs (shRNAs). Immunoblotting and qPCR analysis showed that both CTNND1 shRNAs noticeably reduced CTNND1 protein (Figure 6A and Supplementary Figure 5A) and mRNA (Supplementary Figure 5B) levels in both cell lines. Consistent with the above results (Figure 3A–3F), wound healing and transwell migration and invasion assays revealed that overexpression of MORC2 enhanced cell migration and invasion as compared with empty vector control (Figure 6B–6F). In contrast, knockdown of endogenous CTNND1 attenuated MORC2-enhanced cell migration and invasion (Figure 6B–6F). These data suggests that MORC2 promotes migration and invasion of breast cancer cells through, at least in part, a CTNND1 mediated mechanism.

DISCUSSION

Development of metastatic spread is the leading cause of mortality in patients with breast cancer, thus the elucidation of the molecular determinants of breast cancer cell invasion and metastasis is of crucial importance. The key findings of this work lie in the following. First, it establishes MORC2 as a novel regulator of breast cancer invasion and metastasis. Second, it provides mechanistic insights into the metastasis-promoting activity of MORC2.

Figure 4: Identification of the binding partners of MORC2 using IP coupled with LC-MS/MS. (A) Schematic representation of experimental design. (B, C) HEK293T cells stably expressing pCDH, Flag-MORC2 WT, and Flag-MORC2 ΔPRD were subjected to IP analysis with an anti-Flag antibody (B), and the bound proteins were isolated on 8% SDS-PAGE gel and stained using Coomassie brilliant blue (C). (D) LC-MS/MS was used to identify the interacting proteins of Flag-MORC2 WT and Flag-MORC2 ΔPRD. The numbers of the identified proteins in each group are shown. (E) The proteins that specifically interacted with Flag-MORC2 WT were subjected to biological pathway analyses using DAVID.
in breast cancer depending, at least in part, on its PRD domain. Third, it identifies CTNND1 as a novel binding partner of MORC2, which is required for MORC2-mediated breast cancer migration and invasion.

MORC is a poorly characterized, highly conserved nuclear protein family from prokaryotic to eukaryotic cells [6, 61, 62]. The evolutionary contextual and gene neighborhood studies on prokaryotic MORCs predict that their eukaryotic counterparts may be implicated in the regulation of chromatin remodeling through DNA superstructure manipulation [7, 61]. Indeed, our recent study demonstrated that MORC2 is a chromatin remodeling protein in response to DNA damage and is involved in DNA damage repair [7]. Moreover, the role of MORC2 in gene transcription has been documented in gastric cancer cells [8, 10, 11]. Here, we provide in vitro and in vivo evidence that MORC2 is dispensable for cell proliferation and cell-cycle progression, but promotes breast cancer invasion and metastasis in vitro and in vivo.

Structurally, MORC2 contains several functional domains, including a conserved GHKL (Gyrase, Hsp90, Histidine kinase, and MutL)-type ATPase domain, a CW-type zinc finger domain (ZF-CW), and a PRD domain [6, 7, 9]. We demonstrated that the ATPase domain is required for the ATP-dependent chromatin remodeling activity of MORC2 following DNA damage [7]. Recent structural and biochemical studies have defined the ZF-CW domain as a histone modification reader module [63]. In contrast, the biological function of the PRD domain in MORC2 has not been characterized. Previous studies have demonstrated that the PRD domain is an important structural module found in diverse tumor suppressor proteins and oncoproteins. For instance, the PRD domain in tumor suppressor protein p53 contributes to the regulation of its protein stability and p53-mediated apoptosis and tumor suppression [54, 55, 64, 65]. The PRD domain in the metastasis-associated colon cancer protein 1 (MACC1) is required for its oncogenic function in colon cancer growth and metastasis [66]. Similarly, the proline-rich motif is required for the activation and the biological functions of Akt kinase [67]. To address the contribution of the PRD domain to MORC2 functions in breast cancer development and progression, we generated a PRD domain deletion mutant of MORC2 (ΔPRD), and discovered that the PRD domain is dispensable for the stability and subcellular localization of MORC2, but is required for MORC2-mediated migration, invasion, and metastasis.

The PRD domain has been shown to be important for mediating protein-protein interaction [20]. To address

![Figure 5: MORC2 interacts with CTNND1 through its PRD domain.](image-url)
the molecular mechanisms by which MORC2 promotes breast cancer invasion and metastasis through its PRD domain, we further identified CTNND1 as a novel MORC2-binding partner by LC-MS/MS and biochemical analyses. CTNND1 is deregulated in the majority of human cancers [25] and could act as either a tumor suppressor or an oncogene depending on its subcellular localization [24]. When expressed in cell membrane, CTNND1 functions as a tumor suppressor by stabilizing E-cadherin [27, 28, 34]. However, loss of E-cadherin during tumor progression leads to the cytoplasmic and nuclear translocation of CTNND1 [33, 35, 44]. Cytosolic CTNND1 drives E-cadherin-deficient cancer cell migration, invasion and metastasis through activation of Rho-family GTPases Rac1 and Cdc42 and inhibition of RhoA activity [33, 40]. Nuclear CTNND1 has been observed in invasive breast cancer [35]. Previous studies have reported that nuclear CTNND1 can interact and functionally antagonize the activity of the transcriptional repressor Kaiso, thus regulating expression of Kaiso target genes including matrix metalloproteinase 7 (MMP7) [48], metastasis-associated gene 2 (MTA2) [68], and Wnt11 (WNT11) [50]. Recently, Wnt11-induced Wnt signaling has been identified as a major paracrine factor driving breast cancer invasion [69]. Our data revealed an essential role for endogenous CTNND1 in MORC2-enhanced migration and invasion of E-cadherin-deficient MDA-MB-231 and Hs578T breast cancer cells (Figure 6). As MORC2 is predominately localized in the nuclear (Figure 1E) [7], we hypothesized that the involvement of MORC2-CTNND1 interaction in breast cancer progression is mainly mediated by nuclear CTNND1. In addition, whether the interaction of MORC2 with CTNND1 could affect the interaction between CTNND1 and Kaiso as well as Kaiso target gene expression is needed to be investigated in the future.

Figure 6: Knockdown of endogenous CTNND1 suppresses MORC2-enhanced cell migration and invasion. (A) MDA-MB-231 and Hs578T cells stably expressing wild-type MORC2 were infected with two different CTNND1 shRNA expression vectors. The effect of CTNND1 knockdown was verified by immunoblotting with the indicated antibodies. (B, C) Wound-healing analysis of stable MDA-MB-231 and Hs578T cells expressing the indicated plasmids. Representative images (B) and quantitative results (C) of wound-healing assays are shown. (D–F) Cell migration and invasion were examined by transwell migration and invasion assay. Representative images (D) and quantitative results of migrated (E) and invaded (F) cell number are shown.
In summary, we provide the evidence for the first time that MORC2 promotes the migratory, invasive and metastatic potential of breast cancer, which depends, at least in part, on its PRD domain. These findings provide significant evidence for the understanding of metastatic mechanisms of breast cancer and exploring new therapeutic strategy for preventing breast cancer metastasis. One limitation of this study is that only two triple-negative breast cancer cell lines (MDA-MB-231 and Hs578T) were used in our study. Thus, whether the metastasis-promoting activity of MORC2 and the interaction between MORC2 and CTNND1 could apply to other breast cancer subtypes remain to be addressed in the future.

**MATERIALS AND METHODS**

**Cell culture**

Human breast cancer MCF-7, T47D, SK-BR-3, BT474, MDA-MB-231, MDA-MB-436, MDA-MB-468, Hs578T, and HCC1937 cell lines, normal breast epithelial MCF10A and HBL100 cell lines, and human embryonic kidney 293T (HEK293T) cell line were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cell lines were authenticated through monitoring cell vitality, mycoplasma contamination, DNA fingerprinting, and isozymes. MCF10A cells were cultured in DMEM/F12 (Cellgro, Manassas, VA, USA) supplemented with 5% donor horse serum (Gibco, Carlsbad, CA, USA), 10 μg/ml insulin, 20 ng/ml human epidermal growth factor, 0.5 μg/ml hydrocortisone, and 100 ng/ml cholera toxin. Other cell lines were maintained in DMEM or RPMI1640 media (Cellgro) supplemented with 10% fetal bovine serum (FBS) (Gibco). These cell lines were expanded and frozen immediately into numerous aliquots after arrival. The cells revived from the frozen stock were used within 10–15 passages and not exceeding a period of 6 months. The cells were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cell lines were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise noted.

**Plasmids and transfection**

Myc-DDK-tagged human MORC2 and GFP-tagged human CTNND1 expression vectors were purchased from Origene (Rockville, MD, USA). Flag-MORC2 WT and Flag- MORC2 ΔPRD were constructed by PCR amplification (Primers are listed in Supplementary Table 2) and then subcloned into the lentiviral vector pCDH-CMV-MCS-EF1-Puro (System Biosciences, Mountain View, CA, USA). CTNND1 shRNA expression vectors were cloned into pLKO.1-GFP-shRNA expressions vector (Kindly provided by Prof. Xin-Yuan Liu, Institute of Biochemistry and Cell Biology, Chinese Academy of Science, Shanghai, China) using primers listed in Supplementary Table 3. The lentiviral and packaging vectors were transfected into HEK293T packaging cells using Lipofectamine 2000 (Thermo Fisher, Waltham, MA, USA) or Teng-fect (TengYi Biotech, Shanghai, China) transfection reagents. The supernatant containing viruses was collected 48 h after transfection, filtered, and used for infecting target cells in the presence of 8 μg/ml polybrene prior to drug selection with 2 μg/ml puromycin (Cayman Chemical, Ann Arbor, MI, USA) for one week.

**Cell viability, colony-formation assay, and cell cycle analysis**

Cells were seeded in 96-well plates (1000 cells per well) in triplicate and cell viability was examined using Cell Counting Kit-8 (CCK-8) kit (Dojindo Laboratories, Kumamoto, Japan). For colony-formation assay, cells were seeded in 6-well plates (1000 cells per well) in triplicate and cultured under normal growth conditions for 2 weeks. Colonies were stained with 0.1% crystal violet and counted. For cell cycle analysis, cells were harvested and fixed in 70% ethanol overnight. After PBS wash, cells were stained with cell cycle staining kit (MultiSciences Biotech, Hangzhou, China), and analyzed on a BD FACSCanto II flow cytometer (BD Bioscience, San Jose, CA, USA).

**Migration, invasion, and lung colonization assays**

For wound-healing assays, cells were seeded in 6-well plates. When cells were grown to confluency, the wound was created by 200 μl tips, the floated cells were removed through PBS washing, and the culture medium was replaced by DMEM containing 0.1% FBS. Images were taken at the indicated time points and the wound closure ratios were calculated.

Migration and invasion assays were conducted using 8-μm pore polycarbonate transwell inserts and BioCoat Matrigel Invasion Chambers (Corning, New York, NY, USA), respectively, as described previously [70]. Briefly, cells (transwell migration assays: 2.5 × 10⁵ cells for MDA-MB-231 and 1.0 × 10⁵ cells for Hs578T; transwell invasion assays: 5 × 10⁴ cells for MDA-MB-231 and 2.5 × 10⁵ cells for Hs578T) were plated in the top chamber using growth medium containing 0.5% FBS. Growth medium containing 10% FBS was used as a chemotaxiant in the lower chamber. After 24 h, migrated and invaded cells were fixed and stained with 0.1% crystal violet. Cells were counted under an inverted microscope at 200× magnification.

For lung colonization experiments, 2.25 × 10⁶ cells in 300 μl of PBS were injected in the tail vein of 5–6 week-old BALB/c female nude mice (5 mice per group). After 6 weeks of injection, the lungs were excised, fixed in Bouin solution overnight, and surface lung colonies were counted under a Nikon SMZ1500 stereomicroscope (Nikon, Japan).
Tokyo, Japan). In addition, paraffin-embedded sections were stained by hematoxylin and eosin (HE) to examine the presence of micrometastases. All animal experiments were approved by Institutional Animal Care and Use Committee of Fudan University and animal care was in accordance with institutional guidelines.

**Quantitative real-time PCR (qPCR)**

Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and converted to cDNA using PrimeScript RT Master Mix (Takara, Dalian, China). qPCR analyses were performed using FastStart Universal SYBR Green Master (Roche, Shanghai, China). Primer information is described in Supplementary Table 4.

**Antibodies, immunoblotting, immunoprecipitation, and immunofluorescence**

The detailed information for primary antibodies used in this study is provided in Supplementary Table 5. Immunoblotting, immunoprecipitation (IP), and indirect immunofluorescence (IF) staining were conducted as described previously [7, 71]. Briefly, protein extracts were prepared using modified RIPA buffer, resolved by SDS-PAGE, and transferred onto PVDF membrane (Millipore, Billerica, MA, USA), followed by antibody detection using enhanced chemiluminescence (Yeasen, Shanghai, China). For IP assay, 1–2 mg of both exogenously and endogenously expressed proteins was incubated with 1–2 µg of the indicated antibodies overnight at 4°C. Protein A/G magnetic beads (Bimake, Houston, TX, USA) were used to pull down the protein-antibody complex. The resulting complexes were washed and subjected to immunoblotting. For indirect IF staining, cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100, and blocked in 10% normal goat serum in PBS. Cells were incubated with primary antibodies, washed three times in PBS, and then incubated with the appropriate secondary antibody conjugated with 555-Alexa (red) or 488-Alexa (green) (Cell Signaling Technology, Danvers, MA, USA), respectively. DNA staining was performed using fluoroshield mounting medium with DAPI (Abcam, Cambridge, MA, USA). Microscopic analyses were performed using a Leica SP5 confocal laser scanning microscopy (Leica Microsystems, Buffalo Grove, IL, USA).

**Proteomic assay**

Liquid chromatography tandem mass spectrometry (LC-MS/MS) assay was performed as described previously [72] to analyze MORC2 interacting complex.

**Statistical analysis**

All data are presented as the mean ± standard error from at least three independent experiments. The Student’s t-test was used for assessing the difference between individual groups and p ≤ 0.05 was considered statistically significant.

**Abbreviations**

CTNND1, catenin delta 1; MORC2, MORC family CW-type zinc finger 2; IF, immunofluorescence; IP, immunoprecipitation; LC-MS/MS, liquid chromatography tandem mass spectrometry; PRD, proline-rich domain.

**Author contributions**

XHL and YZ conducted all functional experiments and data analysis. WJD cloned CTNND1 shRNA expression vectors. ZMS and DQL supervised the study. DQL and XHL drafted the manuscript. All authors have read and approved the final manuscript.

**ACKNOWLEDGMENTS**

We sincerely acknowledge the staff members of the pathology core facility (Shanghai Cancer Center), the proteomic center (Institute of Biomedical Sciences), the animal resource center (State Key Laboratory of Oncogene and Related Gene), and members in the Li laboratory for their excellent technical assistance.

**CONFLICTS OF INTEREST**

The authors have declared that no conflicts of interest exists.

**FUNDING**

The work in the Li laboratory is supported, in whole or in part, by the National Natural Science Foundation of China (No. 81372847 and 81572584), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 2013-06), and New Investigator Start-up Fund from Fudan University (All to DQL).

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67:7–30.
2. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436:518–524.
3. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N,
et al. Tumour exosome integrins determine organotrophic metastasis. Nature. 2015; 527:329–335.

4. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3:537–549.

5. Bos PD, Zhang XH, Nakazato R, Shu W, Gomis R, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J. Genes that mediate breast cancer metastasis to the brain. Nature. 2009; 459:1005–1009.

6. Li DQ, Nair SS, Kumar R. The MORC family: new epigenetic regulators of transcription and DNA damage response. Epigenetics. 2013; 8:685–693.

7. Li DQ, Nair SS, Ohshiro K, Kumar A, Nair VS, Pakala SB, Reddy SD, Gajula RP, Eswaran J, Aravind L, Kumar R. MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. Cell Reports. 2012; 2:1657–1669.

8. Shao Y, Li Y, Zhang J, Liu D, Liu F, Zhao Y, Shen T, Li F. Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX. Nucleic Acids Res. 2010; 38:2813–2824.

9. Wang GL, Wang CY, Cai XZ, Chen W, Wang XH, Li F. Identification and expression analysis of a novel CW-type zinc finger protein MORC2 in cancer cells. Anat Rec (Hoboken). 2010; 293:1002–1009.

10. Tong Y, Li Y, Gu H, Wang C, Liu F, Shao Y, Li J, Cao L, Li F. Microchidia protein 2, MORC2, downregulates the cytoskeleton adapter protein, ArgBP2, via histone methylation in gastric cancer cells. Biochem Biophys Res Commun. 2015; 467:821–827.

11. Zhang Q, Song Y, Chen W, Wang X, Miao Z, Cao L, Li F, Wang G. By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. Oncotarget. 2015; 6:16461–16470. https://doi.org/10.18632/oncotarget.3889.

12. Sanchez-Solana B, Li DQ, Kumar R. Cytosolic functions of MORC2 in lipogenesis and adipogenesis. Biochem Biophys Acta. 2014; 1843:316–26.

13. Wang G, Song Y, Liu T, Wang C, Zhang Q, Liu F, Cai X, Miao Z, Xu H, Xu H, Cao L, Li F. PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis. Oncotarget. 2015; 6:9877–86. https://doi.org/10.18632/oncotarget.3185.

14. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, Antoine GA, Hirsch EF, Kavanah M, Mendez J, Stone M, Gery NP, Lenburg ME, Rosenberg CL. Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer. 2008; 122:1557–1566.

15. Chen LH, Kuo WH, Tsai MH, Chen PC, Hsiao CK, Chuang EY, Chang LY, Hsieh FJ, Lai LC, Chang KJ. Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. PLoS One. 2011; 6:e28222.

16. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA. 1996; 93:15335–15340.

17. Gu W, Helms V. Dynamical binding of proline-rich peptides to their recognition domains. Biochim Biophys Acta. 2005; 1754:232–238.

18. Panni S, Salvioli S, Santonico E, Langone F, Storino F, Altitha S, Franceschi C, Cesareni G, Castagnoli L. The adapter protein CD2AP binds to p53 protein in the cytoplasm and can discriminate its polymorphic variants P2R. J Biochem. 2015; 157:101–111.

19. Zhu J, Jiang J, Zhou W, Zhu K, Chen X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene. 1999; 18:2149–2155.

20. Zarrinpars A, Bhattacharyya RP, Lim WA. The structure and function of proline recognition domains. Sci STKE. 2003; 2003:RE8.

21. Reynolds AB, Roesel DJ, Kanmer SB, Parsons JT. Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol. 1989; 9:629–638.

22. Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N, Johnson KR, Wheelock MJ, Matsuoyoshi N, Takeichi M. Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes. J Cell Biol. 1995; 128:949–957.

23. Staddon JM, Smales C, Schulze C, Esch FS, Rubin LL, p120, a p120-related protein (p100), and the cadherin/catenin complex. J Cell Biol. 1995; 130:369–381.

24. Reynolds AB, Rocznik-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004; 23:7947–7956.

25. van Hengel J, van Roy F. Diverse functions of p120ctn in tumors. Biochim Biophys Acta. 2007; 1773:78–88.

26. Ireten RC, Davis MA, van Hengel J, Mariner DJ, Barnes K, Thoreson MA, Anastasiadis PZ, Matrisian L, Bundy LM, Sealy L, Gilbert B, Van Roy F, Reynolds AB. A novel role for p120 catenin in E-cadherin function. J Cell Biol. 2002; 159:465–476.

27. Davis MA, Ireten RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol. 2003; 163:525–534.

28. Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, Reichardt LF. Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol. 1989; 9:629–638.

29. Yanagisawa M, Anastasiadis PZ. p120 catenin is essential for E-cadherin function. J Cell Biol. 2002; 159:465–476.

30. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. The structure and function of the avian cellular src gene. Mol Cell Biol. 1989; 9:629–638.

31. Reynolds AB, Roesel DJ, Kanmer SB, Parsons JT. Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol. 1989; 9:629–638.

32. Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N, Johnson KR, Wheelock MJ, Matsuoyoshi N, Takeichi M. Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes. J Cell Biol. 1995; 128:949–957.

33. Staddon JM, Smales C, Schulze C, Esch FS, Rubin LL. p120, a p120-related protein (p100), and the cadherin/catenin complex. J Cell Biol. 1995; 130:369–381.

34. Reynolds AB, Rocznik-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004; 23:7947–7956.

35. van Hengel J, van Roy F. Diverse functions of p120ctn in tumors. Biochim Biophys Acta. 2007; 1773:78–88.

36. Ireten RC, Davis MA, van Hengel J, Mariner DJ, Barnes K, Thoreson MA, Anastasiadis PZ, Matrisian L, Bundy LM, Sealy L, Gilbert B, Van Roy F, Reynolds AB. A novel role for p120 catenin in E-cadherin function. J Cell Biol. 2002; 159:465–476.

37. Davis MA, Ireten RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol. 2003; 163:525–534.

38. Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, Reichardt LF, Ikura M. Dynamic and static interactions between p120 catenin and the cadherin/catenin complex. J Cell Biol. 1995; 128:949–957.

39. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991; 66:107–119.
31. Fri xen U H, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991; 113:173–185.

32. Thoreson MA, Anastasiadis PZ, Daniel JM, Ireton RC, Wheelock MJ, Johnson KR, Hummingbird DK, Reynolds AB. Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol. 2000; 148:189–202.

33. Shihata T, Kokubu A, Sekine S, Kanai Y, Hirohashi S. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol. 2004; 164:2269–2278.

34. Thoreson MA, Reynolds AB. Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation. 2002; 70:583–589.

35. Sarrio D, Perez-Mies B, Hardisson D, Moreno-Bueno G, Suarez A, Cano A, Martin-Perez J, Gamallo C, Palacios J. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene. 2004; 23:3272–3283.

36. van Hengel J, Vanhoenacker P, Staes K, van Roy F. Nuclear localization of the p120(ctn) Armadillo-like catenin is counteracted by a nuclear export signal and by E-cadherin expression. Proc Natl Acad Sci U S A. 1999; 96:7980–7985.

37. Rocznia Fergusson A, Reynolds AB. Regulation of p120-catenin nucleocyttoplasmic shuttling activity. J Cell Sci. 2003; 116:4201–4212.

38. Anastasiadis PZ. p120-ctn: A nexus for contextual signaling via Rho GTPases. Biochim Biophys Acta. 2007; 1773:34–46.

39. Noren NK, Liu BP, Burridge K, Kreft B. p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J Cell Biol. 2000; 150:567–580.

40. Grosheva I, Shtutman M, Elbaum M, Bershadsky AD. p120 catenin affects cell motility via modulation of activity of Rho-family GTPases: a link between cell-cell contact formation and regulation of cell locomotion. J Cell Sci. 2001; 114:695–707.

41. Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, Copland JA, Anastasiadis PZ. A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem. 2008; 283:18344–18354.

42. Strumane K, Bonnomet A, Stove C, Vandenbroucke R, Nawrocki-Raby B, Bruyneel E, Mareel M, Birembaut P, Berx G, van Roy F. E-cadherin regulates human Nanos1, which interacts with p120ctn and induces tumor cell migration and invasion. Cancer Res. 2006; 66:10007–10015.

43. Wildenberg GA, Dohn MR, Camahna RH, Davis MA, Lobdell NA, Settleman J, Reynolds AB. p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell. 2006; 127:1027–1039.

44. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res. 2005; 65:10938–10945.

45. Kelly KF, Spring CM, Otchere AA, Daniel JM. NLS-dependent nuclear localization of p120ctn is necessary to relieve Kaiso-mediated transcriptional repression. J Cell Sci. 2004; 117:2675–2686.

46. Daniel JM. Dancing in and out of the nucleus: p120(ctn) and the transcription factor Kaiso. Biochim Biophys Acta. 2007; 1773:59–68.

47. Daniel JM, Reynolds AB. The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol Cell Biol. 1999; 19:3614–3623.

48. Daniel JM, Spring CM, Crawford HC, Reynolds AB, Baig A. The p120(ctn)-binding partner Kaiso is a bio-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides. Nucleic Acids Res. 2002; 30:2911–2919.

49. Spring CM, Kelly KF, O‘Kelly I, Graham M, Crawford HC, Daniel JM. The catenin p120ctn inhibits Kaiso-mediated transcriptional repression of the beta-catenin/TCF target gene matrilysin. Exp Cell Res. 2005; 305:253–265.

50. Kim SW, Park JI, Spring CM, Sater AK, Ji H, Otchere AA, Daniel JM, McCrea PD. Non-canonical Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. Nat Cell Biol. 2004; 6:1212–1220.

51. Adams CJ, Yu JS, Mao JH, Jen KY, Costes SV, Wade M, Shoemake J, Aina OH, Del Rosario R, Menchavez PT, Cardiff RD, Wahl GM, Balmain A. The Trp53 delta proline (Trp53DeltaP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development. Mol Carcinog. 2016; 55:1387–1396.

52. Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002; 21:9–21.

53. Campbell HG, Mehta R, Neumann AA, Rubio C, Baird M, Slatter TL, Braithwaite AW. Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain of p53. Mol Carcinog. 2002; 22:4517–4523.

54. Edwards SJ, Hananeia L, Eccles MR, Zhang YF, Braithwaite AW. The proline-rich region of mouse p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002; 21:9–21.

55. Campbell HG, Mehta R, Neumann AA, Rubio C, Baird M, Slatter TL, Braithwaite AW. Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene. 2013; 32:827–836.

56. Edwards SJ, Hananeia L, Eccles MR, Zhang YF, Braithwaite AW. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene. 2003; 22:4517–4523.
57. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10:515–527.

58. Singer AL, Bunnell SC, Obstfeld AE, Jordan MS, Wu JN, Myung PS, Samelson LE, Koretzky GA. Roles of the proline-rich domain in SLP-76 subcellular localization and T cell function. J Biol Chem. 2004; 279:15481–15490.

59. Toledo F, Lee CJ, Krummel KA, Rodewald LW, Liu CW, Wahl GM. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol. 2007; 27:1425–1432.

60. Schackmann RC, Klarenbeek S, Vlug EJ, Stelloo S, van Amersfoort M, Tenhagen M, Braumuller TM, Vermeulen JF, van der Groep P, Peeters T, van der Wall E, van Diest PJ, Jonkers J, et al. Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling. Cancer Res. 2013; 73:4937–4949.

61. Iyer LM, Abhiman S, Aravind L. MutL homologs in restriction-modification systems and the origin of eukaryotic MORC ATPases. Biol Direct. 2008; 3:8.

62. Iyer LM, Anantharaman V, Wolf MY, Aravind L. Comparative genomics of transcription factors and chromatin proteins in parasitic protists and other eukaryotes. Int J Parasitol. 2008; 38:1–31.

63. He F, Umehara T, Saito K, Harada T, Watanabe S, Yabuki T, Kigawa T, Takahashi M, Kuwasako K, Tsuda K, Matsuda T, Aoki M, Seki E, et al. Structural insight into the zinc finger CW domain as a histone modification reader. Structure. 2010; 18:1127–1139.

64. Berger M, Vogt Sionov R, Levine AJ, Haupt Y. A role for the polyproline domain of p53 in its regulation by Mdm2. J Biol Chem. 2001; 276:3785–3790.

65. Dumaz N, Milne DM, Jardine LJ, Meek DW. Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem J. 2001; 359:459–464.

66. Stein U, Walther H, Arit F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009; 15:59–67.

67. Jiang T, Qiu Y. Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem. 2003; 278:15789–93.

68. Yoon HG, Chan DW, Reynolds AB, Qin J, Wong J. N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol Cell. 2003; 12:723–734.

69. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151:1542–1556.

70. Ha NH, Nair VS, Reddy DN, Mudvari P, Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L, Lipton A, Badwe RA, Fuqua S, Wallon M, et al. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011; 71:7259–7269.

71. Li DQ, Pakala SB, Reddy SD, Ohshiro K, Zhang JX, Wang L, Zhang Y, Moreno de Alboran I, Pillai MR, Eswaran J, Kumar R. Bidirectional autoregulatory mechanism of metastasis-associated protein 1-alternative reading frame pathway in oncogenesis. Proc Natl Acad Sci USA. 2011; 108:8791–8796.

72. Zhao J, Yu H, Lin L, Tu J, Cai L, Chen Y, Zhong F, Lin C, He F, Yang P. Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF). J Proteomics. 2011; 75:588–602.